Credit Suisse is injecting $250 million into Israeli life-sciences Venture Capital fund aMoonII. The fund invests in mid- to late-stage life science companies in the field of digital health and bio-techs that operate in Israel, the US and Europe.
Credit Suisse’s $250 million for medical investment
This entry was posted in Economy & Business. Bookmark the permalink.